Bromosporine,
1619994-69-2,
Carbamic acid, N-[3-methyl-6-[4-methyl-3-[(methylsulfonyl)amino]phenyl]-1,2,4-triazolo[4,3-b]pyridazin-8-yl]-, ethyl ester,
Bioomosporine,
Bromorsporine,
GTPL8234,
CHEMBL3133807,
SCHEMBL17359131,
C17H20N6O4S,
AOB6807,
Bromosporine, >=98% (HPLC),
HMS3653C21,
KS-00000T5O,
2286AH,
MFCD26142669,
s7233,
ZINC95616589,
AKOS024458332,
CS-3240,
NCGC00351471-11,
AK175193,
HY-15815,
QC-10870,
A4186,
SW219727-1,
J3.656.836D,
ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate,
ethyl (3-methyl-6-{4-methyl-3-[(methylsulfonyl)amino]phenyl}[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate,
ethyl N-[6-(3-methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate,
ethyl N-[6-[3-(methanesulfonamido)-4-methylphenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate,
N-[(6-3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate,
D07ALG,
ACN-034716,
A13163,
ethyl 3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-ylcarbamate,